AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus Releases New Study Examining Consumer Perceptions of Pharmaceutical Companies
Insights are intended to guide innovations and reforms within the industry
Hoboken, New Jersey: Innoplexus, a leader in artificial intelligence and data analytics solutions for pharmaceutical and life science research, announced today the publication of a new study examining consumer perceptions about drug prices, transparency, and other issues related to the pharmaceutical industry. This survey of over 1,000 American consumers was commissioned by Innoplexus and conducted by Haven Insights, a leading research firm that works with organizations such as Stanford, MIT, and P&G.
Top insights from the study include:
- Negative views of pharmaceutical companies increase with age, with 63% of respondents over 60 having a “very negative” or “negative” view of pharmaceutical companies compared to just 36% of 30-39 year-olds.
- 73% said that their opinion of pharma companies would improve if companies were more transparent about what goes into the cost of medications.
- 82% of consumers rate drug prices as “very” or “extremely” important in shaping their perception of the pharma industry, and 77% believe that prices are unreasonably high.
“We commissioned this survey to analyze deeply the priorities, concerns, and hopes that shape the public’s perception of pharmaceutical companies,” said Gunjan Bhardwaj, CEO of Innoplexus, “We hope that these insights can contribute to necessary reforms and drive innovations within the industry to build better relationships between pharma companies and patients.”
Get the details:
About Innoplexus
Innoplexus AG offers Data-as-a-Service and Continuous Analytics-as-a-Service products and solutions that help organizations move towards continuous decision-making. By leveraging cutting-edge Artificial Intelligence and Deep Learning technologies, Innoplexus helps organizations generate insights from structured and unstructured private and public data. Founded in 2011, INNOPLEXUS AG is headquartered in Eschborn, Germany with offices in Pune, India, and Hoboken, USA. Learn more at https://www.innoplexus.com.
For questions or comment contact our agency of record:
Andrew Sears, Front Lines Media | e: andrew@frontlines.io c: 949-230-2651
Featured News
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trialsBOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
New app for cancer patients
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…
Innoplexus wins Silver Edison Award for OntosightⓇ Explore
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary…
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific…
How can AI be leveraged for Clinical Trial Prediction?
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years…
Innoplexus launches new Blockchain platform for Pharma innovation
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be…